Welcome to our dedicated page for Onco-Innovations news (Ticker: ONNVF), a resource for investors and traders seeking the latest updates and insights on Onco-Innovations stock.
News for Onco-Innovations Limited (ONNVF) centers on its activities in oncology research, preclinical drug development, AI-enabled precision medicine, and corporate financing. The company describes itself as a Canadian-based oncology-focused organization with an exclusive worldwide license to patented technology targeting solid tumours, including its PNKP Inhibitor Technology platform.
Investors and observers following Onco-Innovations’ news can expect updates on the advancement of its PNKP Inhibitor Technology (A83B4C63), including manufacturing milestones with Dalton Pharma Services such as process optimization, intermediate scale-up, analytical method development, and preparation for potential future clinical material production. Releases also cover collaborations with partners like Kuano Ltd., where quantum-ready molecular modelling and AI-driven compound design are being applied to deepen understanding of PNKP inhibition and guide next-generation therapeutic candidates.
Another important stream of news involves Onco-Innovations’ subsidiary Inka Health and its SynoGraph platform. Announcements have highlighted publications on the transportability of real-world evidence, integration of advanced statistical methods into SynoGraph, and participation in precision oncology forums with organizations such as Colorectal Cancer Canada. These items illustrate how the company links AI, real-world data, and oncology decision-making.
Corporate and capital markets developments also feature in the news flow. Onco-Innovations has reported private placements, board appointments, marketing engagements, and its intention to pursue a potential Nasdaq cross-listing with the support of a U.S. investment bank. For a consolidated view of these scientific, strategic, and financing updates, this news page provides a single location to review the company’s disclosed developments over time.
Onco-Innovations (OTCQB:ONNVF) CEO Thomas O'Shaughnessy was featured in an exclusive interview on Conversations That Matter, discussing the company's developments in cancer treatment and AI integration. The interview highlighted:
The company's focus on developing novel treatment for colorectal cancer and solid tumors, utilizing precision medicine to enhance traditional therapies. Their proprietary technology, developed by University of Alberta Cancer Institute scientists, employs targeted inhibitors and nanotechnology to disrupt cancer cell replication while preserving healthy tissue.
The interview also covered their recent acquisition of Inka Health AI, which is developing AI tools to optimize patient identification and enhance clinical trial efficacy. The company maintains strategic partnerships with Quantify Research and AstraZeneca Canada to advance precision medicine approaches in cancer therapeutic development.
Onco-Innovations (OTCQB:ONNVF) subsidiary Inka Health has published a groundbreaking study protocol in medRxiv focusing on AI-generated synthetic patient models for oncology research. The study, titled 'ECLIPSE', leverages advanced machine learning to create synthetic patient data, particularly beneficial for rare cancer research where traditional patient data is scarce.
Led by Dr. Winson Cheung, Medical Advisor at Inka Health and Professor at the University of Calgary, alongside Inka Health co-founders Dr. Paul Arora and Dr. Alind Gupta, the research aims to develop synthetic patient cohorts using AI technology. The initiative utilizes Inka's proprietary AI platform, SynoGraph, to enhance patient stratification and improve clinical trial efficiency.
The technology focuses on generating comparator arms for trials, addressing a critical challenge in rare cancer research where randomizing patients to control groups is often unfeasible. This approach aims to accelerate drug development and regulatory processes in the pharmaceutical and biotech industries.
Onco-Innovations has announced that its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound has demonstrated enhanced PNKP inhibitor delivery with minimal toxicity. A June 2021 study by the University of Alberta revealed that the technology was well-tolerated at therapeutic doses in mice with colorectal cancer, showing no signs of toxicity such as weight loss or adverse effects. This formulation, tested as a targeted therapy for PTEN-deficient colorectal cancer, showed promising results in both in vitro and in vivo evaluations.
The study involved treating mice with the PKNP nanoparticle formulation (NP/A83) over a 22-day period, while a control group received placebo injections. Both biochemical and histopathological examinations confirmed the absence of toxicity in major organs. Dose-escalating toxicity studies on healthy CD-1 mice indicated that both free and nano-encapsulated PNKP inhibitors were safe at doses of ≤50 mg/kg. The findings suggest potential for developing safer and more effective cancer treatments with fewer side effects.
Thomas O'Shaughnessy, CEO, emphasized the technology's promise for future therapeutic development due to its low toxicity profile, laying a foundation for continued research and development.
Onco-Innovations (OTCQB:ONNVF) announced that its subsidiary, Inka Health, filed a provisional patent application with the USPTO for SynoGraph, its next-generation AI platform, on January 28, 2025. The application, titled 'Method and System for Causal Graph Generation and Analysis,' aims to protect their AI-driven precision medicine approach.
SynoGraph utilizes AI-powered causal inference to identify cancer patients likely to respond to specific treatments. The platform integrates various medical data types including genomics, transcriptomics, and proteomics to uncover insights for treatment decisions and clinical trial design. The technology is expected to enhance Onco's drug research initiatives by potentially streamlining trial design and patient selection, which could reduce development costs and improve patient outcomes.
Onco-Innovations (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H) has announced the commencement of trading its common shares on the OTCQB marketplace under the symbol 'ONNVF'. The company will maintain its listing on the Canadian Securities Exchange under 'ONCO'.
This strategic move to the OTCQB Venture Market is designed to enhance the company's visibility and accessibility to U.S. investors, potentially expanding its shareholder base. CEO Thomas O'Shaughnessy emphasized that this listing represents a significant milestone for the company's growth strategy in driving oncology innovation.
The OTCQB Venture Market provides a platform for early-stage and growth companies to increase their U.S. market presence, with real-time quotes and market information available at otcmarkets.com.